💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Biofil Chemicals and Pharmaceuticals Limited is an India-based company, which is engaged in manufacturing and trading pharmaceutical products. The Company operates through two segments: the Pharmaceutical Division and the Chemicals Division. It is also involved in the…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, fast-growing business, trading cheap versus its own history — but flagged on governance.
Biofil Chem & Pharma is scored on the pharma / healthcare framework. It keeps a slim 8.9% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT -0.22×) — worth a closer look. Free cash flow is worth about 1.1% of its market value.
Over the last 3 years revenue compounded at 2%/yr and profit at 71%/yr. Book value has grown 8%/yr. Return on equity is a healthy 12.9%. In the latest quarter profit fell 48% versus the prior quarter.
At 18× earnings, the stock sits at the 4th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price already implies ~31%/yr earnings growth sustained for a decade — a demanding bar. The forensic screen raises 2 red flags: Only ₹-0.05 of cash per ₹1 profit over 4 years — earnings not converting to cash; 89% of pre-tax profit is other income, not operations.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 101.33 | — | — |
| P/B | 2.29 | 4.11 | better |
| EV/EBITDA | 44.84 | 19.15 | worse |
| ROE | 12.92 | — | — |
| ROCE | 14.07 | 6.87 | better |
| ROA | 1.12 | 1.26 | worse |
| Quick Ratio | 1.54 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue declined 7% in the latest year — a break from prior trajectory. 1% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
Profit is growing faster than revenue (71% vs 1%) — margin expansion is at work. The latest year saw a +398% swing — check if it's a one-off or structural.
Operating margin has expanded from 3% to 11% — the business is keeping more of each rupee earned.
ROE at 13% — a respectable return on shareholder capital. Capital efficiency improving — ROE up 10pp across the window.
71% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
3 of 4 years had negative operating cash flow — profitability on paper may not translate to cash.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 62% sequentially — momentum is building. Wide quarterly swings (93% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 38% above earlier ones.
Profit fell 48% QoQ — one-quarter drops can be noise, but a pattern matters.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 46.8% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.